Abstract
Hundreds of genetically characterized cell lines are available for the discovery of genotype-specific cancer vulnerabilities. However, screening large numbers of compounds against large numbers of cell lines is currently impractical, and such experiments are often difficult to control. Here we report a method called PRISM that allows pooled screening of mixtures of cancer cell lines by labeling each cell line with 24-nucleotide barcodes. PRISM revealed the expected patterns of cell killing seen in conventional (unpooled) assays. In a screen of 102 cell lines across 8,400 compounds, PRISM led to the identification of BRD-7880 as a potent and highly specific inhibitor of aurora kinases B and C. Cell line pools also efficiently formed tumors as xenografts, and PRISM recapitulated the expected pattern of erlotinib sensitivity in vivo.
Original language | English (US) |
---|---|
Pages (from-to) | 419-423 |
Number of pages | 5 |
Journal | Nature Biotechnology |
Volume | 34 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2016 |
Externally published | Yes |
ASJC Scopus subject areas
- Applied Microbiology and Biotechnology
- Biotechnology
- Molecular Medicine
- Bioengineering
- Biomedical Engineering